Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe

To objective of this study is to investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda® in adults aged 65 years or older under routine clinical practice, as per approved indications This is an open-label, multi-center, observational active safety surveillance study, designed to be conducted under standard healthcare setting of the Republic of Korea, in accordance with "Regulation on the Operation of Risk Management Plans". The study duration of each participation will be approximately 28 to 35 days. In the event that Visit 2 is not made, the study duration would be extended to 36 to 42 days.

NCT Number	NCT07282795
Lead Sponsor	Sanofi
Conditions	Influenza Immunization, Healthy Volunteers
Enrollment	670 participants
Start Date	2026-10-01
Primary Completion	2029-02-22 (estimated)
Study Completion	2029-03-20 (estimated)
Updated on ClinicalTrials.gov	2026-03-31